Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Efficacy of Biosimilar Infliximab-Dyyb in Non-Infectious Uveitis. Ocul Immunol Inflamm 2024 Oct;32(8):1517-1521

Date

08/15/2023

Pubmed ID

37582248

DOI

10.1080/09273948.2023.2244071

Scopus ID

2-s2.0-85168003212 (requires institutional sign-in at Scopus site)   5 Citations

Abstract

PURPOSE: To describe the frequency of uveitis recurrences in patients with non-infectious uveitis treated with the biosimilar infliximab-dyyb.

DESIGN: Retrospective case series.

METHODS: Records of uveitis patients treated with the biosimilar infliximab-dyyb between 2016 and 2022 at two institutions were reviewed. Data extracted included patient demographics, diagnosis, previous originator infliximab use, additional immunosuppression medications, infliximab-dyyb use, reason for switch, disease activity, and follow-up time.

RESULTS: A total of 14 patients were identified. Seven patients were switched from originator infliximab to a biosimilar for nonmedical/non-ocular reasons (insurance prompted the switch). One patient was started directly on infliximab-dyyb due to active joint disease despite well-controlled uveitis. None of these eight patients developed inflammation after the switch. Six patients were started directly on infliximab-dyyb due to poorly controlled uveitis. Of these, five patients achieved disease quiescence during follow-up. The mean dose of originator was 1.79 mg/kg/week, with a median dosing schedule of 4 weeks prior to therapy with infliximab-dyyb. The mean final infliximab-dyyb dosage was 1.81 mg/kg/week, with a median dosing schedule of 4 weeks.

CONCLUSION: Infliximab-dyyb appears to be efficacious in achieving and maintaining uveitis control.

Author List

Zaguia F, Randerson EL, Moorthy RS, Goldstein DA

Author

Edward L. Randerson MD Assistant Professor in the Ophthalmology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Aged
Biosimilar Pharmaceuticals
Drug Substitution
Female
Follow-Up Studies
Humans
Infliximab
Male
Middle Aged
Recurrence
Retrospective Studies
Treatment Outcome
Uveitis
Young Adult